KR102827354B1 - 폐암의 검출 및 치료 방법 - Google Patents

폐암의 검출 및 치료 방법 Download PDF

Info

Publication number
KR102827354B1
KR102827354B1 KR1020247002923A KR20247002923A KR102827354B1 KR 102827354 B1 KR102827354 B1 KR 102827354B1 KR 1020247002923 A KR1020247002923 A KR 1020247002923A KR 20247002923 A KR20247002923 A KR 20247002923A KR 102827354 B1 KR102827354 B1 KR 102827354B1
Authority
KR
South Korea
Prior art keywords
ser
thr
pro
leu
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020247002923A
Other languages
English (en)
Korean (ko)
Other versions
KR20240015172A (ko
Inventor
사미르 한나쉬
아유무 다구치
지딩 펑
Original Assignee
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 filed Critical 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템
Publication of KR20240015172A publication Critical patent/KR20240015172A/ko
Application granted granted Critical
Publication of KR102827354B1 publication Critical patent/KR102827354B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G16B5/20—Probabilistic models
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Probability & Statistics with Applications (AREA)
  • Physiology (AREA)
  • Signal Processing (AREA)
  • Artificial Intelligence (AREA)
  • Bioethics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Evolutionary Computation (AREA)
KR1020247002923A 2017-02-09 2018-02-09 폐암의 검출 및 치료 방법 Active KR102827354B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762456731P 2017-02-09 2017-02-09
US62/456,731 2017-02-09
KR1020197026040A KR102630885B1 (ko) 2017-02-09 2018-02-09 폐암의 검출 및 치료 방법
PCT/US2018/017704 WO2018148600A1 (en) 2017-02-09 2018-02-09 Methods for the detection and treatment of lung cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197026040A Division KR102630885B1 (ko) 2017-02-09 2018-02-09 폐암의 검출 및 치료 방법

Publications (2)

Publication Number Publication Date
KR20240015172A KR20240015172A (ko) 2024-02-02
KR102827354B1 true KR102827354B1 (ko) 2025-06-30

Family

ID=63107741

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197026040A Active KR102630885B1 (ko) 2017-02-09 2018-02-09 폐암의 검출 및 치료 방법
KR1020247002923A Active KR102827354B1 (ko) 2017-02-09 2018-02-09 폐암의 검출 및 치료 방법

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020197026040A Active KR102630885B1 (ko) 2017-02-09 2018-02-09 폐암의 검출 및 치료 방법

Country Status (8)

Country Link
US (1) US12405274B2 (enExample)
EP (2) EP3580560B1 (enExample)
JP (1) JP7311417B2 (enExample)
KR (2) KR102630885B1 (enExample)
CN (2) CN117368475A (enExample)
CA (1) CA3053116A1 (enExample)
ES (1) ES2995959T3 (enExample)
WO (1) WO2018148600A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102630885B1 (ko) 2017-02-09 2024-01-29 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 폐암의 검출 및 치료 방법
US20220260573A1 (en) * 2019-07-29 2022-08-18 Biomark Cancer Systems Inc. Method of discriminating lung cancer patients
US20230213521A1 (en) * 2020-04-28 2023-07-06 Luxembourg Institute Of Health (Lih) Biomarkers for detection of lung cancer
CA3191405A1 (en) * 2020-09-01 2022-03-10 Ali Ya KHAMMANIVONG Predictive diagnostic test for early detection and monitoring of diseases
CN112147099A (zh) * 2020-09-22 2020-12-29 范庆坤 一种m蛋白紫外分光检测法
EP4222287A4 (en) * 2020-10-02 2024-12-18 Board of Regents, The University of Texas System METHODS FOR THE DETECTION AND TREATMENT OF LUNG CANCER
EP4357782A1 (en) * 2022-10-18 2024-04-24 MU Bioteknik Aktiebolag Protein biomarker panel for the diagnosis of colorectal cancer
CN115575636B (zh) * 2022-11-22 2023-04-04 杭州广科安德生物科技有限公司 一种用于肺癌检测的生物标志物及其系统
CN116593702B (zh) * 2023-05-11 2024-04-05 杭州广科安德生物科技有限公司 一种肺癌的生物标志物以及诊断系统
CN118983078B (zh) * 2024-08-15 2025-03-25 立本医疗器械(成都)有限公司 基于ptr-tof-ms的肺癌筛查模型构建方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008144034A1 (en) 2007-05-18 2008-11-27 Duke University Serum biomarkers for the early detection of lung cancer
WO2011140234A1 (en) 2010-05-07 2011-11-10 Abbott Laboratories Methods for predicting sensitivity to treatment with a targeted tyrosine kinase inhibitor
US20130196868A1 (en) 2011-12-18 2013-08-01 20/20 Genesystems, Inc. Methods and algorithms for aiding in the detection of cancer
US20140271453A1 (en) 2013-03-14 2014-09-18 Abbott Laboratories Methods for the early detection of lung cancer
US20140274772A1 (en) 2013-03-15 2014-09-18 Rush University Medical Center Biomarker panel for detecting lung cancer
US20150072890A1 (en) 2013-09-11 2015-03-12 20/20 Gene Systems, Inc. Methods and compositions for aiding in the detection of lung cancer
US20160060329A1 (en) 2014-07-28 2016-03-03 Donald SIN Compositions and methods for the diagnosis and prognosis of lung cancer
JP2016176954A (ja) * 2005-12-22 2016-10-06 アボツト・モレキユラー・インコーポレイテツド 肺がんへの傾向についてのスクリーニングのための方法およびマーカー組合せ

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080133141A1 (en) * 2005-12-22 2008-06-05 Frost Stephen J Weighted Scoring Methods and Use Thereof in Screening
US20120087860A1 (en) * 2010-05-24 2012-04-12 Marek Malecki Methods for in vivo cancer detection, diagnosis and therapy using multidomain biotags
US20130078642A1 (en) 2010-06-03 2013-03-28 Porto Conte Richerche S.R.L. Biomarkers for lung neuroendocrine tumors
CN102321760A (zh) * 2011-08-26 2012-01-18 泸州医学院附属医院 一种非小细胞肺癌标志物及应用
CA3029063C (en) 2015-06-26 2023-09-05 Biomark Cancer Systems Inc. Method of detecting lung cancer
JP6903672B2 (ja) 2016-03-08 2021-07-14 マグアレイ，インコーポレイテッド 肺癌の診断および治療のための蛋白質と自己抗体バイオマーカー
CN105717146B (zh) * 2016-03-29 2018-11-09 复旦大学附属中山医院 一种基于ct影像及生物标志物谱针对中国城市人口高危人群的肺癌风险预测试剂盒
KR102630885B1 (ko) 2017-02-09 2024-01-29 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 폐암의 검출 및 치료 방법
EP4222287A4 (en) * 2020-10-02 2024-12-18 Board of Regents, The University of Texas System METHODS FOR THE DETECTION AND TREATMENT OF LUNG CANCER

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016176954A (ja) * 2005-12-22 2016-10-06 アボツト・モレキユラー・インコーポレイテツド 肺がんへの傾向についてのスクリーニングのための方法およびマーカー組合せ
WO2008144034A1 (en) 2007-05-18 2008-11-27 Duke University Serum biomarkers for the early detection of lung cancer
WO2011140234A1 (en) 2010-05-07 2011-11-10 Abbott Laboratories Methods for predicting sensitivity to treatment with a targeted tyrosine kinase inhibitor
US20130196868A1 (en) 2011-12-18 2013-08-01 20/20 Genesystems, Inc. Methods and algorithms for aiding in the detection of cancer
US20140271453A1 (en) 2013-03-14 2014-09-18 Abbott Laboratories Methods for the early detection of lung cancer
US20140274772A1 (en) 2013-03-15 2014-09-18 Rush University Medical Center Biomarker panel for detecting lung cancer
US20150072890A1 (en) 2013-09-11 2015-03-12 20/20 Gene Systems, Inc. Methods and compositions for aiding in the detection of lung cancer
US20160060329A1 (en) 2014-07-28 2016-03-03 Donald SIN Compositions and methods for the diagnosis and prognosis of lung cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Don D Sin et al, Journal of Clinical Oncology (2013.12.20.), vol 31, no 36, pp 4536-4543.
William R Wikoff et al, Journal of Clinical Oncology (2015.11.20.), vol 33, no 33, pp 3880-3886.

Also Published As

Publication number Publication date
US12405274B2 (en) 2025-09-02
US20230314436A1 (en) 2023-10-05
EP4528741A3 (en) 2025-04-09
KR102630885B1 (ko) 2024-01-29
WO2018148600A1 (en) 2018-08-16
EP3580560B1 (en) 2024-10-02
EP3580560A1 (en) 2019-12-18
ES2995959T3 (en) 2025-02-11
EP3580560A4 (en) 2020-12-09
US20200025766A1 (en) 2020-01-23
JP2020510816A (ja) 2020-04-09
EP4528741A2 (en) 2025-03-26
JP7311417B2 (ja) 2023-07-19
KR20190116368A (ko) 2019-10-14
CN117368475A (zh) 2024-01-09
CN110291397A (zh) 2019-09-27
KR20240015172A (ko) 2024-02-02
CA3053116A1 (en) 2018-08-16

Similar Documents

Publication Publication Date Title
KR102827354B1 (ko) 폐암의 검출 및 치료 방법
Zhang et al. The important role of circulating CYFRA21-1 in metastasis diagnosis and prognostic value compared with carcinoembryonic antigen and neuron-specific enolase in lung cancer patients
US20240159753A1 (en) Methods for the detection and treatment of lung cancer
Lycke et al. Consideration should be given to smoking, endometriosis, renal function (eGFR) and age when interpreting CA125 and HE4 in ovarian tumor diagnostics
Nagy et al. Serum human epididymis protein 4 (HE4) as a tumor marker in men with lung cancer
Roe et al. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case–control study
Basso et al. Peptidomic and proteomic analysis of stool for diagnosing IBD and deciphering disease pathogenesis
Di Noia et al. Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory “FoRECATT” study
He et al. Baseline and early changes in circulating Serum Amyloid A (SAA) predict survival outcomes in advanced non-small cell lung cancer patients treated with Anti-PD-1/PD-L1 monotherapy
Reix et al. A novel machine learning-derived decision tree including uPA/PAI-1 for breast cancer care
Jannawan et al. High level of serum coiled-coil domain containing 25 (CCDC25) as a diagnostic marker for cholangiocarcinoma but not for other cancers
WO2024107923A1 (en) Methods for the detection and treatment of lung cancer
Xiong et al. Protein expression profiling identifies a prognostic model for ovarian cancer
CN108369233B (zh) 基于标志物人附睾蛋白4 (he4)检测肺腺癌的复发的方法及相关用途
US12504430B2 (en) Methods for the detection and treatment of lung cancer
EP4413372A1 (en) Lung cancer prediction and uses thereof
Tcherkassova et al. Diagnostic significance of the novel biomarker combination for early-stage non-small cell lung cancer detection: results of the blind clinical study
WO2024249401A2 (en) Methods for the detection and treatment of lung cancer
Majidova et al. Prognostic value of systemic inflammatory markers in renal cell carcinoma with isolated lung metastases: A retrospective analysis
Tahanovich et al. Blood laboratory parameters can predict relapse-free survival of patients with advanced squamous cell lung cancer and adenocarcinoma
CN116529603A (zh) 用于检测和治疗肺癌的方法
Majidova et al. İzole akciğer metastazlı renal hücreli karsinomda sistemik inflamatuvar belirteçlerin prognostik önemi: Retrospektif inceleme
HK1259002B (en) Methods of detecting a relapse of a lung adenocarcinoma based on marker human epididymis protein 4 (he4) and related uses

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20240124

Application number text: 1020197026040

Filing date: 20190904

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240416

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250326

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250626

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250626

End annual number: 3

Start annual number: 1

PG1601 Publication of registration